Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets 
Toyota Raises FY2027 Outlook, Announces ¥1 Trillion Buyback Despite Q1 Profit Dip 
SK Hynix Bonus Dispute Deepens as Union Rejects Stock-Based Payout Proposal 
Trump Urges Exxon, Chevron to Cut Gas Prices After Record Oil Profits 
Prysmian Nears Deal to Acquire Atkore in Potential All-Cash Takeover 
Shein Targets $30B-$40B Valuation in Hong Kong IPO Planned for August 
SpaceX Earnings Preview: Bernstein Says 4 Key Factors Will Drive Long-Term Valuation 
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
Palantir Stock Soars as AI Demand Drives Strong Q2 Earnings and Higher 2026 Outlook 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
Apple Restores Telegram to App Store After Content Policy Violation 
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions 
BYD July Global Vehicle Sales Rise 22% as Overseas Demand Surges 
Telegram Restored on Apple App Store After Temporary Removal 
Alibaba Stock Jumps as Qwen 3.8-MAX AI Model Intensifies China's AI Race 
Chery Invests $75 Million in KG Mobility to Expand Global Automotive Partnership 
PLANO, Texas, April 11, 2016 -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that Scott Drees, Chief Executive Officer, and Walter Berger, Chief Financial Officer, are scheduled to present at the 15th Annual Needham Healthcare Conference in New York, NY.
| Event: | 15th Annual Needham Healthcare Conference |
| Date: | Wednesday, April 13, 2016 |
| Time: | 9:20 am ET |
A webcast of the Company’s presentation will be available by visiting the investor relations section of Nuvectra’s website at www.nuvectramed.com. A webcast replay of the presentation will be available for 90 days.
About Nuvectra Corporation
Nuvectra™ is a neurostimulation company committed to helping physicians improve the lives of people with chronic neurological conditions. The Algovita® Spinal Cord Stimulation (SCS) System is our first commercial offering and is CE marked and FDA approved for the treatment of chronic pain of the trunk and/or limbs. Our innovative technology platform also has capabilities under development to support other neurological indications such as sacral nerve stimulation (SNS), and deep brain stimulation (DBS). In addition, our NeuroNexus subsidiary designs, manufactures and markets leading-edge neural-interface technologies for the neuroscience clinical research market. Visit the Nuvectra website at www.nuvectramed.com.
Company Contacts: Nuvectra Corporation Walter Berger, Chief Financial Officer (972) 668-4106 [email protected] Jennifer Armstrong, Media Relations (214) 618-4823 [email protected] Investor Contacts: The Ruth Group Nick Laudico (646) 536-7030 [email protected] Zack Kubow (646) 536-7020 [email protected]
